Sphingosine kinase type 1 inhibitors
Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
1. A compound selected from
or a pharmaceutically acceptable salt thereof,
wherein R is selected from a straight carbon chain, a branched carbon chain, a straight carbon chain comprising one or more heteroatoms, a branched carbon chain comprising one or more heteroatoms, a cyclic ring, a heterocyclic ring, an aromatic ring, a hetero-aromatic ring, or any combination of the foregoing.
2. The compound of claim 1 having the structure
3. The compound of claim 1 having the structure
4. The compound of claim 1 having the structure
5. The compound of claim 1 having the structure
6. The compound of claim 1 having the structure
7. The compound of claim 1 having the structure
8. The compound of claim 1 having the structure
9. The compound of claim 8 , wherein R is 3,4-dimethoxy.
10. The compound of claim 8 , wherein R is 4-phenyl.
11. The compound of claim 8 , wherein R is 3-pentyl.
12. The compound of claim 1 , wherein the compound inhibits sphingosine kinase 1 greater than sphingosine kinase 2.